HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $16 price target.
July 10, 2023 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Panbela Therapeutics and maintained a $16 price target, which could positively impact the stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and a maintained price target of $16 by HC Wainwright & Co. indicates their continued confidence in Panbela Therapeutics, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100